Global biopharmaceutical company
Appears in 5 stories
Executing two-horizon growth strategy; undergoing R&D leadership transition
Andy Plump, who rebuilt Takeda's drug pipeline over 12 years and steered the $62 billion Shire acquisition, will retire as president of R&D in June 2027. He announced the plan on September 10 but stays until a successor is named.
Updated Yesterday
Markets Mimrylo in the United States
Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug mimicking hepcidin, the hormone that limits iron for red blood cell production.
Updated Sep 1
Global partner outside Greater China
Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.
Updated Jun 4
Developing competing TYK2 inhibitor zasocitinib (TAK-279) in Phase 3
For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.
Updated May 30
Sponsor and owner of zasocitinib; preparing FDA filings and broader immunology expansion
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
